Compare Quest Diagnostics Inc (DGX) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs MINISO Group Holding Ltd — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while MINISO Group Holding Ltd trades at $12.37 (market cap $3.46B). The key difference: Quest Diagnostics Inc is far larger — about 6.6× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.78%). Which is the better fit depends on your goals.
| DGX | MNSO | |
|---|---|---|
Market Cap | $22.80B | $3.46B |
Sector | Health | Technology |
52-Week High | $216.02 | $26.63 |
52-Week Low | $166.42 | $11.30 |
Enterprise Value | $28.82B | $4.13B |
Dividend Yield | 1.67% | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
MNSO trades at $11.42, down 3.14% on the day, reflecting recent volatility. The stock shows mixed signals with a bearish technical trend but solid fundamentals, including a P/E of 11.73 and net income margin of 8.98%. Recent corporate actions include a $0.38 dividend and a HK$2 billion share repurchase program announced on June 29, 2026, signaling management confidence. Q1 2026 earnings beat expectations with EPS of $0.591 versus $0.238 expected, though prior quarters missed estimates.
Outlook is cautiously optimistic given strong profitability metrics and shareholder-friendly actions, but risks include margin pressures from overseas expansion and technical bearishness. With 75% analyst buy ratings and an undervalued GF Score per GuruFocus on June 29, 2026, the stock offers value if execution improves, though investors should monitor earnings consistency and global economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
